<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770845</url>
  </required_header>
  <id_info>
    <org_study_id>NUTRIPF</org_study_id>
    <nct_id>NCT03770845</nct_id>
  </id_info>
  <brief_title>Nutritional Assessment in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>NUTRIPF</acronym>
  <official_title>Nutritional Assessment in Idiopathic Pulmonary Fibrosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Gerardo Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Gerardo Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years nutritional status assumed increasing importance in the evaluation of chronic&#xD;
      respiratory diseases, considering that their clinical course is often characterized by a&#xD;
      progressive loss of weight and reduction of muscle mass.In regards to Idiopathic Pulmonary&#xD;
      Fibrosis (IPF), to date there are no studies that fully assessed the nutritional status of&#xD;
      patients, nor the impact of the introduction of specific anti-fibrotic agents on the&#xD;
      nutritional status of these patients.&#xD;
&#xD;
      Aim of this study is to assess the nutritional status of patients with IPF at the time of&#xD;
      diagnosis and the impact of the introduction of specific anti-fibrotic agents, pirfenidone or&#xD;
      nintedanib, on the nutritional status itself.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary studies on Idiopathic Pulmonary Fibrosis (IPF) seem to suggest that nutritional&#xD;
      status has an impact on clinical outcomes, as already demonstrated in COPD. However, few data&#xD;
      regarding this subject are available for patients with IPF.&#xD;
&#xD;
      Primary aim of this study is to assess the nutritional status of patients diagnosed with mild&#xD;
      to moderate IPF at the time of disease diagnosis. To do so, the investigators assess the&#xD;
      prevalence of nutritional disorders at baseline through nutritional scores evaluated with&#xD;
      specific questionnaires and through the identification of the following metabolic phenotypes&#xD;
      (based on those previously applied in COPD): cachexia, sarcopenia, normal nutritional status,&#xD;
      obesity, sarcopenic obesity.&#xD;
&#xD;
      Secondary aims of this study are:&#xD;
&#xD;
        -  the evaluation of the impact of the introduction of an anti-fibrotic pharmacological&#xD;
           agent (pirfenidone or nintedanib) on the nutritional status of patients (modification of&#xD;
           metabolic phenotypes and nutritional scores) evaluated at 6 months from the initiation&#xD;
           of antifibrotic therapy.&#xD;
&#xD;
        -  the assessment of calcium and vitamin D metabolism, by blood sampling, in patients&#xD;
           diagnosed with mild to moderate IPF at the time of disease diagnosis and at 6 months&#xD;
           from the initiation of antifibrotic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FFMI (fat free mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SMI (skeletal muscle mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BFMI (body fat mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hand Grip</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malnutrition Universal Screening Tool (MUST) Screening Tool (MUST)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Nutritional Assessment (MNA)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>questionnaire score (maximum score 30): total score &gt; 23.5 = normal nutritional status; total score &lt; 23.5 = inadequate nutritional status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFMI (fat free mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SMI (skeletal muscle mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BFMI (body fat mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Grip</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malnutrition Universal Screening Tool (MUST)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Nutritional Assessment (MNA)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>questionnaire score (maximum score 30): total score &gt; 23.5 = normal nutritional status; total score &lt; 23.5 = inadequate nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma calcium</measure>
    <time_frame>baseline (IPF diagnosis) and 6 months after baseline</time_frame>
    <description>calcium level in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma vitamin D</measure>
    <time_frame>baseline (IPF diagnosis) and 6 months after baseline</time_frame>
    <description>vitamin D level in plasma</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of mild to moderate Idiopathic Pulmonary Fibrosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age greater than or equal to 18 years;&#xD;
&#xD;
          -  diagnosis of IPF according to the ATS / ERS 2011 guidelines with multidisciplinary&#xD;
             discussion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe renal failure, defined as a GFR (glomerular filtration rate) lower than 30ml /&#xD;
             min;&#xD;
&#xD;
          -  NYHA class IV;&#xD;
&#xD;
          -  severe liver failure, defined as Child-Pugh score class C;&#xD;
&#xD;
          -  active solid or haematological neoplasms;&#xD;
&#xD;
          -  having already received (currently or in the past) therapy with pirfenidone or&#xD;
             nintedanib;&#xD;
&#xD;
          -  inability to walk without help;&#xD;
&#xD;
          -  need for oxygen therapy at rest;&#xD;
&#xD;
          -  participation in other interventional experimental protocols with use of a medicinal&#xD;
             product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>INRCA Casatenovo</name>
      <address>
        <city>Casatenovo</city>
        <state>Lecco</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Salvini Hospital</name>
      <address>
        <city>Garbagnate Milanese</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Giuseppe Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Paolo and San Carlo Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Gerardo Hospital</investigator_affiliation>
    <investigator_full_name>Paola Faverio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nutritional status</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

